Aperio Group’s Coherus Oncology CHRS Stock Holding History

Aperio Group’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-3,626	Closed	-$80K	–	2393
2019 Q2	$80K	Buy	+3,626	New	+$63K	﹤0.01%	2444

Other funds holding CHRS

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Aperio Group's CHRS Position: Q3 2019 in Review

Aperio Group sold out of Coherus Oncology (CHRS) in Q3 2019, closing a stake of 3,626 shares — an estimated $80K sold.

Aperio Group first reported a position in CHRS in Q2 2019 and held it in 1 quarter. The position peaked at $80K in Q2 2019. 167 funds tracked by Wall St. Rank hold CHRS as of Q3 2019.

Aperio Group reported no remaining Coherus Oncology position as of Q3 2019 after selling out during the quarter.
Aperio Group sold 3,626 Coherus Oncology shares in Q3 2019, an estimated $80K.
Aperio Group first reported a position in Coherus Oncology in Q2 2019 and held it in 1 quarter.
Aperio Group's Coherus Oncology position peaked at $80K in Q2 2019.
167 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.